Patient centricity
At Grifols, patients are at the heart of our mission to improve global health and well-being. We uphold the highest standards of quality and safety in our medicines, drive innovation in new therapies and support countries in achieving plasma self-sufficiency.
By fostering trust with patient organizations, we work alongside patient communities to help build a more inclusive healthcare environment.
In addition, to reinforce our commitment to the well-being of the most vulnerable, we provide humanitarian aid and emergency relief through trusted local and international organizations. Read more about our humanitarian aid initiatives.
Patient stories
We work to better understand the patient journey, including the challenges patients face and what it means to live with chronic diseases. The company communicates these experiences across our organization to guide daily decision-making and continue innovating to improve the quality of life of patients.
“My diagnosis took a long time, around 25 years. My situation prior to the diagnosis had been difficult because I spent a lot of time at hospitals, and I was uncertain because I never knew when I wouldn't be able to breathe.”
“I think that we would not be here today without plasma donors. And their donation is very, very important and it is a big part of what we have today. Our health depends on their donations, and I will be forever grateful.”
“Going from not being able to live a normal life, makes normal life much more enjoyable than it would have been otherwise. So, I enjoy things a little bit more because I didn’t always have them.”
“If somebody were recently diagnosed or had a child recently diagnosed, I would say reach out and get support. The immune deficiency community is strong and there’s always somebody who’s willing to answer questions, share ideas.”
Safety and quality as priority requirements
Grifols, we ensure that every scientific advancement is shaped by a strong ethical foundation that protects the health and safety of the patients we serve. This commitment, driven by senior management and endorsed in the Code of Ethics for Grifols Executives, is reflected in the Grifols Corporate Quality Policy and supports the company’s aim to improve health outcomes while delivering long-term, sustainable value to patients, donors, the healthcare community, collaborators and society as a whole.
Grifols' end‑to‑end commitment:
We are dedicated to building a responsible value chain that goes beyond strict regulatory requirements for quality and safety. This includes maintaining rigorous standards from the earliest stages of the process, including plasma donation.
By ensuring the safety and quality of our treatments, we reaffirm our focus on prioritizing the needs of patients, healthcare professionals and customers.
Through a highly regulated and vertically integrated model, we work to safeguard quality and safety, reinforce the trust of all our stakeholders and minimize risks. In this regard, we apply robust quality policies designed to anticipate and prevent potential issues. Our risk‑management policy identifies, assesses and controls risks related to quality, safety and regulatory compliance while our preventive and corrective action policy drives continuous improvement across all operations.
To strengthen transparency and operational rigor, audits are routinely carried out across plasma centers, laboratories, manufacturing facilities and warehouses. We also conduct comprehensive supplier audits through our Supplier Qualification Management System, ensuring that all raw materials meet the required quality standards.
490+
quality control supplier audits performed (2025)
132M
people reached with our treatments (2025)
$28.72B
positive impact on patients (2025)
An ethical approach to science and innovation
We recognize that life sciences must evolve in parallel with responsibility, transparency and respect for human dignity. We are committed to protecting the rights, safety and well-being of patients who participate in clinical trials.
Supporting patient organizations and their communities
Grifols works to maintain trusted relationships with patient organizations, which serve as independent and critical voices for members. Through Patient Affairs, we support these groups with reliable and transparent information in their efforts to increase disease awareness, promote early diagnosis, provide education and support and advocate for improved availability of treatment and care.
Grifols' approach to engaging with patient communities is based on four pillars:
Engagement initiatives are governed by a global policy for patients and patient organizations, which can be read here.
At Grifols, patient centricity is an ethos that is both aspirational and the foundation of a purpose-driven approach to achieving our mission.
Awards to improve care of patients with hemophilia
To support patients with hemophilia in countries with limited economic resources, Grifols in 2019 created the Grifols Hemophilia Awareness Global Awards (GHAGA). The program’s two editions encouraged healthcare providers, hemophilia treatment centers as well as hemophilia societies to drive initiatives that contributed to improving care for hemophilia patients and enhancing their quality of life.
Improving access to treatment
Blood plasma contains hundreds of essential proteins and antibodies vital to the body's ability to maintain critical functions. Thanks to the generosity of plasma donors, we are able to produce plasma-derived medicines that treat chronic, rare, prevalent and, at times, life-threatening conditions.
We work to help countries achieve plasma self-sufficiency and expand global access to plasma-derived medicines, aiming to make essential therapies more widely available. Our commitment has brought us to reach alliances with public systems around the world:
- Grifols Egypt for Plasma Derivatives is the joint venture that we established with the Egyptian government to build the first integrated platform for sourcing and producing plasma medicines in Egypt and the wider region.
- The company also has a long-term agreement with Canadian Blood Services, Canada’s national blood authority, to increase the country’s self-sufficiency in immunoglobulin (Ig) medicines.
In addition, we also run initiatives such as patient assistance and emergency supply programs to address barriers to treatment access.
The patients we serve around the world can lead better lives thanks to donors and the plasma-derived medicines they make possible. Patients drive the work we do every day.
Key therapeutic areas
Our robust therapeutic portfolio is the result of keen insights into multiple disease states for which we’re developing potential treatments, including plasma and non-plasma solutions alike.
Learn more
Caring for people
We strive to create positive social impact in local communities – both donor communities and those where we operate – and in society as a whole.